{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:16:19Z","timestamp":1788668179857,"version":"build-2803163510"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jfma.2026.08.029","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:43:29Z","timestamp":1787744609000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Consensus-based recommendations by the Hematology Society of Taiwan for the management of multiple myeloma in 2026"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3359-1336","authenticated-orcid":false,"given":"Yu-Chin","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9884-9429","authenticated-orcid":false,"given":"Shih-Feng","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7649-2812","authenticated-orcid":false,"given":"Ya-Ting","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4625-0534","authenticated-orcid":false,"given":"Chao-Hung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Kuang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5894-6112","authenticated-orcid":false,"given":"Wei-Han","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7945-9292","authenticated-orcid":false,"given":"Chia-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jfma.2026.08.029_bib2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.jfma.2026.08.029_bib3","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","article-title":"Multiple myeloma, version 3.2021, NCCN Clinical Practice Guidelines in oncology","volume":"18","author":"Kumar","year":"2020","journal-title":"J Natl Compr Cancer Netw : J Natl Compr Cancer Netw"},{"issue":"4","key":"10.1016\/j.jfma.2026.08.029_bib4","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of (18)F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.jfma.2026.08.029_bib5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study","volume":"12","author":"Long","year":"2022","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.jfma.2026.08.029_bib6","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.jfma.2026.08.029_bib7","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple myeloma, version 2.2024, NCCN Clinical Practice Guidelines in oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Cancer Netw : J Natl Compr Cancer Netw"},{"issue":"24","key":"10.1016\/j.jfma.2026.08.029_bib8","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.jfma.2026.08.029_bib9","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.jfma.2026.08.029_bib10","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.jfma.2026.08.029_bib11","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the international staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY Project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jfma.2026.08.029_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.bjhh.2016.01.005","article-title":"Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells","volume":"38","author":"Kishimoto","year":"2016","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"3","key":"10.1016\/j.jfma.2026.08.029_bib13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3343\/alm.2024.0582","article-title":"Factors influencing fluorescence-activated cell sorting for multiple Myeloma fluorescence in situ hybridization: Real-world experience","volume":"45","author":"Choi","year":"2025","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.jfma.2026.08.029_bib14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cancergen.2018.07.002","article-title":"Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: an evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders","volume":"228\u2013229","author":"Pugh","year":"2018","journal-title":"Cancer Genet"},{"issue":"3","key":"10.1016\/j.jfma.2026.08.029_bib15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2020)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jfma.2026.08.029_bib16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjh.17410","article-title":"Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology\/UK Myeloma Forum Guideline","volume":"193","author":"Sive","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jfma.2026.08.029_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/2643-3230.BCD-24-0292","article-title":"Minimal residual disease as an early endpoint for accelerated drug approval in myeloma: a roadmap","volume":"6","author":"Landgren","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"23","key":"10.1016\/j.jfma.2026.08.029_bib18","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jfma.2026.08.029_bib19","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jfma.2026.08.029_bib20","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis","volume":"20","author":"Avet-Loiseau","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.jfma.2026.08.029_bib21","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jfma.2026.08.029_bib22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.6004\/jnccn.2025.0023","article-title":"NCCN guidelines\u00ae insights: multiple myeloma, version 1.2025","volume":"23","author":"Kumar","year":"2025","journal-title":"J Natl Compr Cancer Netw : J Natl Compr Cancer Netw"},{"issue":"9","key":"10.1016\/j.jfma.2026.08.029_bib23","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.jfma.2026.08.029_bib24","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1080\/10428194.2018.1427858","article-title":"Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop","volume":"59","author":"Tan","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"10.1016\/j.jfma.2026.08.029_bib25","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S2152-2650(20)30470-5","article-title":"Management of frail older adults with newly diagnosed multiple myeloma - moving toward a personalized approach","volume":"20","author":"Grant","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.jfma.2026.08.029_bib26","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/imj.16049","article-title":"The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia","volume":"53","author":"Sim","year":"2023","journal-title":"Intern Med J"},{"issue":"1","key":"10.1016\/j.jfma.2026.08.029_bib27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jfma.2026.08.029_bib28","article-title":"Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population","volume":"11","author":"Lee","year":"2021","journal-title":"Sci Rep"},{"issue":"30","key":"10.1016\/j.jfma.2026.08.029_bib29","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/JCO.2016.68.6113","article-title":"Optimizing treatment for elderly patients with newly diagnosed multiple myeloma: a personalized approach","volume":"34","author":"Larocca","year":"2016","journal-title":"J Clin Oncol : official journal of the American Society of Clinical Oncology"},{"issue":"21","key":"10.1016\/j.jfma.2026.08.029_bib66","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1182\/bloodadvances.2020001965","article-title":"Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and\/or refractory multiple myeloma","volume":"4","author":"Facon","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jfma.2026.08.029_bib67","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/asheducation-2018.1.88","article-title":"Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist","volume":"2018","author":"Wildes","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"14","key":"10.1016\/j.jfma.2026.08.029_bib30","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jfma.2026.08.029_bib31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jfma.2026.08.029_bib32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bbmt.2018.09.021","article-title":"High-Dose chemotherapy with early autologous stem cell transplantation compared to standard dose chemotherapy or delayed transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jfma.2026.08.029_bib33","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.clml.2025.06.003","article-title":"SOHO State of the art updates and next questions | Late\/Deferred ASCT in myeloma","volume":"25","author":"Mo","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.jfma.2026.08.029_bib34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1182\/asheducation.V2014.1.255.3885263","article-title":"Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?","volume":"2014","author":"Richardson","year":"2014","journal-title":"Hematology"},{"issue":"4","key":"10.1016\/j.jfma.2026.08.029_bib35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jfma.2026.08.029_bib36","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1200\/JCO-24-02266","article-title":"Isatuximab, lenalidomide, Bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial","volume":"43","author":"Mai","year":"2025","journal-title":"J Clin Oncol : official journal of the American Society of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.jfma.2026.08.029_bib37","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ajh.25797","article-title":"Transplant eligibility in elderly multiple myeloma patients: prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years","volume":"95","author":"Belotti","year":"2020","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.jfma.2026.08.029_bib38","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.bbmt.2014.07.013","article-title":"Older patients with myeloma derive similar benefit from autologous transplantation","volume":"20","author":"Sharma","year":"2014","journal-title":"Biol Blood Marrow Transplant : journal of the American Society for Blood and Marrow Transplantation"},{"issue":"13","key":"10.1016\/j.jfma.2026.08.029_bib39","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2011-11-374249","article-title":"IMWG consensus on maintenance therapy in multiple myeloma","volume":"119","author":"Ludwig","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jfma.2026.08.029_bib40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jfma.2026.08.029_bib41","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/bjh.19353","article-title":"The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma: considerations on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"204","author":"Hwang","year":"2024","journal-title":"Br J Haematol"},{"issue":"29","key":"10.1016\/j.jfma.2026.08.029_bib42","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol : official journal of the American Society of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.jfma.2026.08.029_bib43","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial","volume":"32","author":"Goldschmidt","year":"2018","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.jfma.2026.08.029_bib44","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-Term Follow-Up results of lenalidomide, Bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple Myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J Clin Oncol : official journal of the American Society of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.jfma.2026.08.029_bib45","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","article-title":"Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3","volume":"138","author":"Barlogie","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jfma.2026.08.029_bib46","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.2024025746","article-title":"Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study","volume":"145","author":"Badros","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jfma.2026.08.029_bib47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jfma.2026.08.029_bib48","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/bloodadvances.2024014624","article-title":"Cumulative deficits frailty index and relationship status predict survival in multiple myeloma","volume":"9","author":"Abdallah","year":"2025","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jfma.2026.08.029_bib49","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/ejh.13496","article-title":"Maintenance therapy in transplant ineligible adults with newly-diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"105","author":"Balitsky","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jfma.2026.08.029_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103744","article-title":"Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients","volume":"176","author":"Rafae","year":"2022","journal-title":"Crit Rev Oncol-Hematol"},{"issue":"8","key":"10.1016\/j.jfma.2026.08.029_bib51","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00277-020-04023-4","article-title":"The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma","volume":"99","author":"Merz","year":"2020","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.jfma.2026.08.029_bib52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41408-020-0298-1","article-title":"Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis","volume":"10","author":"Zhang","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.jfma.2026.08.029_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010155","article-title":"How to manage patients with lenalidomide-refractory multiple myeloma","volume":"15","author":"de Arriba de la Fuente","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.jfma.2026.08.029_bib54","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.jfma.2026.08.029_bib55","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jfma.2026.08.029_bib56","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.jfma.2026.08.029_bib57","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jfma.2026.08.029_bib58","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jfma.2026.08.029_bib59","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"10262","key":"10.1016\/j.jfma.2026.08.029_bib60","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.jfma.2026.08.029_bib61","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00277-020-03970-2","article-title":"DCEP and bendamustine\/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma","volume":"99","author":"Goldsmith","year":"2020","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.jfma.2026.08.029_bib62","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5045\/br.2016.51.3.193","article-title":"Bendamustine in heavily pre-treated multiple myeloma patients: results of a retrospective analysis from the Korean Multiple Myeloma Working Party","volume":"51","author":"Kim","year":"2016","journal-title":"Blood Res"},{"issue":"1","key":"10.1016\/j.jfma.2026.08.029_bib63","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/asheducation-2017.1.508","article-title":"Management of multiple myeloma in the relapsed\/refractory patient","volume":"2017","author":"Sonneveld","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.jfma.2026.08.029_bib64","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00277-022-05027-y","article-title":"VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed\/refractory multiple myeloma: a single-center experience","volume":"102","author":"Ghandili","year":"2023","journal-title":"Ann Hematol"},{"issue":"14","key":"10.1016\/j.jfma.2026.08.029_bib65","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood-2008-12-173526","article-title":"Reduced-intensity allogeneic transplantation for myeloma: reality bites","volume":"113","author":"Stewart","year":"2009","journal-title":"Blood"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626008181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626008181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:07:26Z","timestamp":1788667646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664626008181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":66,"alternative-id":["S0929664626008181"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2026.08.029","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus-based recommendations by the Hematology Society of Taiwan for the management of multiple myeloma in 2026","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2026.08.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2026, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}